QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 专题：复旦大学上海医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial 期刊论文 EUROPEAN JOURNAL OF CANCER, 2019, 卷号: 112 作者:  Yuan, Peng;  Hu, Xichun;  Sun, Tao;  Li, Wei;  Zhang, Qingyuan 收藏  |  浏览/下载：19/0  |  提交时间：2019/12/05 Progression-free survival  Tolerability  Locally recurrent or metastatic breast cancer  Eribulin   Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial 期刊论文 LANCET ONCOLOGY, 2019, 卷号: 20, 期号: 6 作者:  Jiang, Zefei;  Li, Wei;  Hu, Xichun;  Zhang, Qingyuan;  Sun, Tao 收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05 Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study 期刊论文 MEDICINE, 2018, 卷号: 97, 期号: 21 作者:  Li, Junjie;  Shao, Zhimin;  Xu, Binghe;  Jiang, Zefei;  Cui, Shude 收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05 adjuvant therapy  breast cancer  HER2-targeted therapy  neoadjuvant therapy  trastuzumab   A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab 会议论文 作者:  Xu, Binghe;  Ma, Fei;  Ouyang, Quchang;  Li, Wei;  Jiang, Zefei 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study 期刊论文 HEALTH AND QUALITY OF LIFE OUTCOMES, 2016, 卷号: 14 作者:  Cao, Ayong;  Zhang, Jin;  Liu, Xiaoan;  Wu, Weizhu;  Liu, Yinhua 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 Quality of life  Prospective  Functional Assessment of Cancer Therapy-Breast  Trial outcome index  Hormone receptor-positive early-stage breast cancer postmenopause  Adjuvant  Aromatase inhibitors  Early breast cancer